主动脉疾病的杂交方法——我们的经验
本文回顾性分析了过去12年在本机构接受主动脉弓杂交胸主动脉腔内修复术(TEVAR)的71例患者结局。术后30天主要并发症发生率为15.7%(3例),30天死亡率为5.2%(1例),平均随访30个月总死亡率仍为5.2%。作者认为单期主动脉弓杂交TEVAR技术可行,中期生存良好且远期免于再干预。
要点
- 过去12年本机构71例主动脉弓杂交TEVAR的回顾性病例系列。
- 术后30天主要并发症3例(15.7%),包括卒中1例、截瘫并肺部并发症1例。
- 30天死亡率为5.2%,平均随访30个月总死亡率仍为5.2%。
核心结论
- 单期主动脉弓杂交TEVAR技术可行,中期生存良好且远期免于再干预。
研究设计与样本
- 回顾性病例系列,回顾过去12年在本机构接受主动脉弓杂交TEVAR的71例患者结局。
主要发现
- 术后30天主要并发症发生于3例患者(15.7%),包括卒中1例和截瘫并肺部并发症1例。
- 1例有多重基础疾病(包括慢性阻塞性肺疾病)的患者于术后第5天因呼吸衰竭院内死亡,30天死亡率为5.2%。
- 平均随访30个月后总死亡率仍为5.2%。
- 随访期间1例患者发生逆行性A型夹层(主要并发症)。
- 随访影像未发现旁路移植血管狭窄,2例患者发现内漏。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite significant technological advancements in endovascular aortic repair, the aortic arch remains a challenge due to anatomic complexity including arch angulation and morphology as well as the location of brachiocephalic vessels in relation to landing zones. Total endovascular solutions are in development and being studied, in the meantime, hybrid thoracic endovascular aortic repair (TEVAR) is a viable alternative to traditional open total arch replacement. METHODS: A retrospective case series was performed reviewing outcomes of 71 patients who underwent hybrid TEVAR in the aortic arch over the past 12 years at our facility. RESULTS: Major morbidity in the first 30 days post procedure was experienced by 3 patients (15.7%) and included one patient with stroke (n = 1), and another who experienced paraplegia and pulmonary complications (n = 1). There was one in-hospital death as a result of respiratory failure in a patient with multiple underlying comorbidities including chronic obstructive pulmonary disease on postoperative day 5 resulting in a 30-day mortality of 5.2%. After a mean follow-up of 30 months, the overall mortality remained 5.2%. Major morbidity occurred in one patient who developed retrograde type A dissection. There was no stenosis of bypass grafts identified on follow-up imaging. Endoleak was identified in 2 patients. One patient experienced persistent retrograde perfusion of the false lumen with interval aneurysmal degeneration which was managed with an Amplatz vascular plug at 120 months following the initial hybrid TEVAR (5.2%). CONCLUSIONS: Single-stage hybrid TEVAR in the aortic arch is technically feasible with a good mid-term survival and a long-term freedom from reintervention.
引用
- Khoynezhad A, Worthington T. Hybrid Approaches for Aortic Disease-Our Experience. Ann Vasc Surg. 2022. PMID: 36377067. doi:10.1016/j.avsg.2022.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。